News | May 08, 2015

Proton Therapy Center Czech First to Employ IBA Motion Management System

Universal Beam Triggering Interface can exchange information between proton therapy system and up to four different motion management systems for more efficient therapy

IBA, Proton Therapy Center Czech, UBTI, Proteus Plus, motion management

May 8, 2015 — IBA (Ion Beam Applications S.A., EURONEXT) announced the first clinical use of its Proteus Plus Universal Beam Triggering Interface (UBTI), a new application in the administration of proton therapy. This interface can connect up to four different patient position monitoring and respiratory management systems to the IBA proton therapy system. The Proton Therapy Center Czech, Prague, Czech Republic, treated a patient using the Qfix breathing control equipment Dyn’R SDXTM connected to UBTI for automatic control of the proton beam according to the tumor motion. As respiratory management systems guide the proton beam more precisely to the tumor, they help leverage the inherent strengths of proton therapy.

Motion management strategies make it possible to decrease treatment margins so the dose to the tumor can be raised while potential toxicity to vital organs is reduced. UBTI can exchange information between the IBA proton system and up to four different motion management systems in order to automatically hold and resume proton as well as X-ray beam irradiation in conjunction with monitored patient parameters, with very low latency. This automated regulation of beam-on/beam-off periods eliminates the burden of manual irradiation pause and resume, increasing performance and safety of treatments.

Integration with UBTI has already been validated for two respiratory management systems: Dyn’R SDXTM and Vision RT gateRT. Both support voluntary breath hold and free-breathing techniques — SDXTM by measuring pulmonary air volume, and gateRT by monitoring skin surface. They are fully compatible with IBA treatment delivery modalities, as beam hold-and-resume is synchronized with delivery cycles so that multiple interrupts do not affect uniformity (in double or uniform scattering) or conformity (in pencil beam scanning) of dose distribution. C-rad has developed an IBA proton system compatible catalyst as well, and others are to follow.

The Proton Therapy Center Czech opted for UBTI-driven assistance of SDXTM with deep inspiration breath hold (DIBH) to support its clinical protocol. Using a spirometer, the SDXTM monitoring device permits beam irradiation when the pulmonary volume reaches a specified level, previously calculated during patient training, and ceases when the patient relaxes his breath hold. Thoracic and abdominal tumor motion can thus be managed during radiotherapy.

Clinicians selected a 48 year-old female with Hodgkin’s lymphoma as the first to receive treatment with UBTI-driven assistance of SDXTM with DIBH. This specific diagnosis was chosen because it affects relatively young patients and leaves them free of respiratory problems, contrary to those with diseases like lung cancer. Treatment was divided into 15 fractions, with a target volume that covers the whole mediastinum and neck nodules. The treatment plan consists of just one field counting about 10 layers, which takes only a few minutes per fraction, each fraction requiring 5 to 7 inspirations from the patient. Computed tomography (CT) imaging and patient alignment are also performed using Dyn’R SDXTM.

Ji?í Kubeš, M.D., Ph.D., medical director of Proton Therapy Center Czech, said: “Integrating a breathing control device into proton therapy is a huge step for our center. Because the preciseness of dose delivery onto the target volume is highly crucial, mandating little or no internal organ motion, we previously had to exclude treating several indications situated in the mediastinum. Now, thanks to the integration of the SDX breathing control device, proton therapy comes within reach of new patient populations that could not be considered for treatment at our center until today.”

For more information: www.iba-worldwide.com

Related Content

BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Overlay Init